$0.59
+0.02 (+3.77%)
Open$0.55
Previous Close$0.57
Day High$0.59
Day Low$0.53
52W High$1.79
52W Low$0.38
Volume—
Avg Volume4.19M
Market Cap19.88M
P/E Ratio—
EPS$-1.31
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+538.2% upside
Current
$0.59
$0.59
Target
$3.76
$3.76
$2.62
$3.76 avg
$5.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.02M | 7.84M | 7.68M |
| Net Income | -31,136,381 | -2,005,672 | -1,738,578 |
| Profit Margin | -619.8% | -25.6% | -22.6% |
| EBITDA | -49,165,725 | -2,263,216 | -2,551,790 |
| Free Cash Flow | — | -1,406,564 | -1,071,377 |
| Rev Growth | — | +12.8% | +0.1% |
| Debt/Equity | 0.06 | 0.17 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |